Golden
COMPASS Pathways

COMPASS Pathways

COMPASS Pathways is a life sciences company founded in 2016, based in London, UK, that develops clinical research programs and treatments for depression and works to accelerate patient access to evidence-based innovations in mental health.

COMPASS Pathways received Breakthrough Therapy designation in Autumn 2018 from the US Food and Drug Administration (FDA) for its psilocybin therapy to treat depression. COMPASS Pathways will run a large-scale psilocybin therapy clinical trial for treatment-resistant depression in Europe and North America in 2018-2019. 



Psilocybin therapy uses psilocybin, the psychoactive ingredient in the psilocybin mushrooms, also known as “magic mushrooms”, and is given along with psychological support. In the UK and the US, Psilocybin therapy how shown promise in terms of efficacy and safety for depression treatment in academic studies. 



COMPASS Pathways is making psilocybin available free of charge through the Medicines Chest programme to the European College of Neuropsychopharmacology (ECNP). 

Timeline

People

Name
Role
Related Golden topics

Ekaterina Malievskaia

Co-Founder, Chief Medical Officer



George Goldsmith

Co-Founder, Chairman



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References